Alternative Guide,is expressed at very low levels in ECs

The vcam 1 binding peptide is a highly specific molecule that plays a crucial role in cellular communication and adhesion. Primarily, it interacts with Vascular Cell Adhesion Molecule-1 (VCAM-1), also known as CD106. This interaction is fundamental to understanding various physiological and pathological processes, particularly those involving the immune system and inflammation.

VCAM-1, a cell adhesion glycoprotein, is predominantly expressed on the surface of endothelial cells. Its expression is typically low in resting endothelial cells but is significantly induced by inflammatory stimuli such as pro-inflammatory cytokines or growth factors. This upregulation is a critical step in the inflammatory response, as it allows for the binding of leukocytes to the blood vessel walls. VCAM-1's primary function is to regulate leukocyte migration across blood vessel walls, facilitating the movement of immune cells from the bloodstream to sites of inflammation or injury.

The vcam 1 binding peptide itself, with a known sequence of VHPKQHRGGSKGC, exhibits high affinity for endothelial cells that express VCAM-1. This specificity makes it a valuable tool in research and potential therapeutic applications. The molecular weight of this peptide is approximately 1390.57, with a chemical formula of C57H95N. It is soluble in pure water, making it convenient for experimental use.

The interaction between VCAM-1 and its binding partners is essential for the rolling and tethering of leukocytes. Specifically, VCAM-1 binds to very late antigen-4 (VLA-4) integrin on the surface of leukocytes. This interaction is a key component of the inflammatory adhesion mechanism, where activated integrins halt rolling leukocytes and attach them to the endothelium. This process is further elaborated by the fact that VCAM-1 supports the adhesion of lymphocytes, monocytes, natural killer cells, eosinophils, and basophils.

Research into vcam 1 binding peptide has explored its utility in various contexts. For instance, VCAM1-binding peptide has been conjugated via linkers like GGSKGC to biomaterials for targeted delivery applications. In one study, VCAM-1-binding peptide-functionalized QDs (VQDs) were developed, highlighting the use of these peptides in creating targeted nanocarriers. Furthermore, VCAM-1-binding peptide targeted cationic liposomes have been investigated as a strategy for interrupting processes like LDL transcytosis, potentially targeting the NLRP3 inflammasome.

The significance of VCAM-1 extends to various diseases. VCAM1 is associated with conditions such as Viral Encephalitis and Chronic Venous Insufficiency. Its role in inflammation and immune cell trafficking has led to its identification as a promising drug target for treating conditions like atherosclerosis and associated cardiovascular disease (CVD). The understanding that VCAM-1 has emerged as a promising drug target underscores the importance of molecules that can modulate its activity, including vcam 1 binding peptide and VCAM1 blocking peptide.

The functionality of vcam 1 binding peptide is further illustrated by studies demonstrating that a cyclic peptide mimicking a specific loop of VCAM-1 can inhibit the binding of alpha 4 beta 1 integrin-bearing cells to VCAM-1. This suggests that specific peptides can effectively block the adhesion process. Indeed, blocking peptides are designed to bind specifically to the target antibody and block antibody binding, often by containing the epitope recognized by the antibody. A VCAM-1 Antibody that recognizes endogenous levels of total VCAM-1 protein is also available for research purposes.

Moreover, research has shown that VCAM-1 via JunB regulates IL-8 promoter activity and expression in human retinal endothelial cells, indicating its involvement in the intricate signaling pathways that govern cellular responses. The tissue expression of VCAM1 reveals its presence in subsets of immune cells and vascular endothelium, with cytoplasmic expression observed.

The development of peptide-based nanosystems for vascular cell adhesion molecule-1 highlights the ongoing efforts to leverage the properties of vcam 1 binding peptide for therapeutic and diagnostic purposes. The binding of leukocytes to VCAM-1 initiates a cascade of intracellular events, including a calcium flux within 30 seconds in endothelial cells, demonstrating the dynamic nature of these cellular interactions.

In summary, the vcam 1 binding peptide is a critical molecular entity that interacts with VCAM-1, a key adhesion molecule involved in immune cell trafficking and inflammation. Its specific binding properties make it a valuable tool for research and a potential target for therapeutic interventions aimed at modulating inflammatory responses and treating a range of diseases. The continuous exploration of VCAM1 binding peptide and related molecules promises further advancements in our understanding and treatment of vascular and immune-related disorders.